Phase 1 N=48 Study of Oral ALXN1840 at 2 Dose Strengths in Healthy Adults
Healthy
Primary: Maximum Observed (Plasma) Concentration (Cmax) of Total Molybdenum — 173.10; 174.27 nanograms (ng)/milliliter (mL)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,578 The Impact of Cigarillo Warnings on Purchasing
Cigar Smoking
Primary: Average Total Number of Cigarillos Purchased — 6.33; 6.28; 6.64; 4.98 cigarillos
N/A N=42 Mobile After-Care Support App: Pilot RCT
Psychotic Disorder
Primary: Client Satisfaction Questionnaire (CSQ) — 23.7; 22.5 score on a scale — p=>0.05
N/A N=36 Evaluation of a Modified Running-specific Prosthetic Foot
Transtibial Amputation
Primary: Metabolic Oxygen Consumption (VO2), Participants With Unilateral Amputation — 1041.1; 1077.4; 1210.9; 1253.5 ml/min — p=.18
Phase 2 N=7 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
Immunoglobulin A Nephropathy
Primary: Change in Slope of First Morning Urinary PCR From the 8-week RAAS Blocker run-in Period to the 12-week CCX168 Treatment Period — -2.4; 15.3; -23.9 mg/g/week — p=0.965
Phase 2 N=1 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II
Acute Myeloid Leukemia · Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Cord Blood Transplant Recipient
Primary: Number of Participants With Dose Limiting Toxicities — 0 Participants
Phase 3 N=68 Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
Pain, Postoperative
Primary: Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME) — 2.00; 5.32 morphine milligram equivalents (MME)
N/A N=5,056 Perioperative Hypothermia and Myocardial Injury After Non-cardiac Surgery
Perioperative Care · Surgery--Complications · Hypothermia; Anesthesia
Primary: Number of Participants With a Composite Outcome Consisted of Myocardial Injury After Non-cardiac Surgery (MINS), Non-fatal Cardiac Arrest, and All-cause Mortality — 239…
Phase 2 N=226 A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Primary: Percent Reduction in EASI Score From Baseline to Week 16 — 57.56; 63.03; 63.50; 39.67 percent reduction from Baseline — p=0.0007
Phase 2 N=23 Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)
Brain Metastases
Primary: Sensitivity of 18F Fluciclovine PET for Detecting Recurrent Brain Metastases at Different Visual Thresholds — 100; 100; 100; 100 percentage of participants
N/A N=26 Nonablative Fractional Diode Laser for Treatment of Skin Resurfacing and Pigmented Lesions
Skin Texture · Pigmented Lesions
Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 observations
Phase 2 N=100 Memantine in Body Focused Repetitive Behaviors
Trichotillomania (Hair-Pulling Disorder) · Dermatillomania
Primary: NIMH Symptom Severity Scale (for TTM or Skin Picking) — -1.19; -6.98 units on a scale
N/A N=61 Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
Female Pattern Hair Loss, Androgenic Alopecia
Primary: Change From Baseline in Investigator's Rating of Global Photographs at Week 12 — 4.9; 4.9; 4.8; 5.0 Score on a scale
N/A N=25 Investigation of a Supporting Ostomy Product Intended for Leakage Detection
Stoma Ileostomy
Primary: System Performance Accuracy of Pictures — 122; 126; 24; 45 Pictures
Phase 2 N=12 Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
Vestibular Schwannoma
Primary: Surgeon Predicted Use of Fluorescein Sodium in Future Cases — 0; 0; 4; 3 participants